ArticleCell host & microbe2015
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
Open access · bronzeAbstract read
In one paragraph
Article in Cell host & microbe, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 73 citations in OpenAlex.
- Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.The Journal of clinical investigation · 2022Trial
- Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells.Frontiers in immunology · 2019Trial
- mGem: Opening Env and harnessing NK cell effector functions to eliminate HIV-1-infected cells.mBio · 2026Review
- Activation of CXCR3Journal of virology · 2025Article
- Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies.Frontiers in immunology · 2025Review
- Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques.Nature communications · 2024Article
- Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted/founder sensitivity to broadly neutralizing antibodies.Nature communications · 2024Article
- Recapitulation of HIV-1 Neutralization Breadth in Plasma by the Combination of Two Broadly Neutralizing Antibodies from Different Lineages in the Same SHIV-Infected Rhesus Macaque.International journal of molecular sciences · 2024Article
- Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity.Frontiers in immunology · 2024Article
- Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted / founder sensitivity to broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2023Article
- Host immunity associated with spontaneous suppression of viremia in therapy-naïve young rhesus macaques following neonatal SHIV infection.Journal of virology · 2023Article
- Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana.Scientific reports · 2023Article
- Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans.NPJ vaccines · 2022Article
- Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.Science advances · 2022Article
- Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses.Cell reports. Medicine · 2021Article
- SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.Microorganisms · 2021Review
- Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.PLoS pathogens · 2021Article
- Article
- To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1.Frontiers in immunology · 2021Review
- Characterizing the Relationship Between Neutralization Sensitivity andFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 14 institutions in 5 countries.
M Anthony MoodyDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA; Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: moody007@mc.duke.edu.
Feng GaoDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: feng.gao@dm.duke.edu.
Thaddeus C GurleyDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Joshua D AmosDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Amit KumarDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Bhavna HoraDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Dawn J MarshallDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
John F WhitesidesDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Shi-Mao XiaDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Krissey E LloydDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Kwan-Ki HwangDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Xiaozhi LuDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Andrés FinziCentre de Recherche du CHUM and Department of Microbiology, Infectology and Immunology, Université de Montréal, Montreal, QC H2X 0A9, Canada and Department of Microbiology and Immunology, McGill University, Montreal, QC H2X 1P1, Canada.
Nathan A VandergriftDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA; Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA; Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Gift KamangaUniversity of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi.
Myron S CohenDepartments of Medicine, Epidemiology, Microbiology, and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
Noel E SamKilimanjaro Christian Medical Center, Moshi 25102, Tanzania.
Saidi KapigaLondon School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Elin S GrayNational Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Nancy L TumbaNational Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Lynn MorrisDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Susan Zolla-PaznerDepartment of Pathology, New York University School of Medicine, New York, NY 10010, USA; Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA.
Miroslaw K GornyDepartment of Pathology, New York University School of Medicine, New York, NY 10010, USA.
John R MascolaVaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Beatrice H HahnPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
George M ShawPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Joseph G SodroskiDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
David C MontefioriDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Peter T HraberLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Bette T KorberLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: hayne002@mc.duke.edu.
Duke Medical Center · USLos Alamos National Laboratory · USNational Institute for Communicable DiseasesUniversity of Pennsylvania · USDuke University · USHarvard University · USKamuzu Central Hospital · MWKilimanjaro Christian Medical Centre · TZMcGill University · CANational Institutes of Health · USNew York University · USUniversity of London · GBUniversity of North Carolina at Chapel Hill · USVA NY Harbor Healthcare System · US
Funding
Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI LETVIN, NORMAN L · 2006 to 2011
$290.5MVirus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MVaccines to Induce Functional Antibodies Targeting the V2 Loop P01AI100151 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WANG, SHIXIA · 2012 to 2017
$15.4MViral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2005 to 2005
$14.9MNIAID NIH HHS P01 AI 100151NIAID NIH HHS P01 AI100151NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI064518NIAID NIH HHS P30-AI-64518NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI100645
Abstract
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently targeted by neutralizing antibodies (nAbs) in infected individuals. In chronic infection, HIV-1 escape mutants repopulate the plasma, and V3 and CD4bs nAbs emerge that can neutralize heterologous tier 1 easy-to-neutralize but not tier 2 difficult-to-neutralize HIV-1 isolates. However, neutralization sensitivity of autologous plasma viruses to this type of nAb response has not been studied. We describe the development and evolution in vivo of antibodies distinguished by their target specificity for V3 and CD4bs epitopes on autologous tier 2 viruses but not on heterologous tier 2 viruses. A surprisingly high fraction of autologous circulating viruses was sensitive to these antibodies. These findings demonstrate a role for V3 and CD4bs antibodies in constraining the native envelope trimer in vivo to a neutralization-resistant phenotype, explaining why HIV-1 transmission generally occurs by tier 2 neutralization-resistant viruses.
Indexed as
Selection, GeneticVirus AttachmentAntibodies, NeutralizingBinding SitesCD4-Positive T-LymphocytesHIV-1HIV AntibodiesHIV Envelope Protein gp120Molecular Sequence DataMutationRNA, ViralSequence Analysis, DNAAntibodies, Neutralizinggp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120RNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.